deamino-arginine-vasopressin has been researched along with Cadaver* in 4 studies
1 trial(s) available for deamino-arginine-vasopressin and Cadaver
Article | Year |
---|---|
Cadaver versus living donor kidneys: impact of donor factors on antigen induction before transplantation.
It is widely recognized that living-related donor (LRD) renal allografts have a higher overall graft survival than cadaver donor transplants. We tested the hypothesis that part of this is attributable to LRD kidneys being obtained under optimal conditions from healthy donors, whereas cadaveric kidneys may have experienced injury as a result of inflammatory events around the time of brain death.. We have performed a comparative immunohistochemical analysis of pretransplant donor biopsies from cadaveric (N = 65) and LRD (N = 29) kidneys to determine any differences that may predispose them to subsequent damage. Cryostat sections were stained with antibodies to leukocytes, adhesion molecules, and human leukocyte antigen (HLA)-DR antigens, and the expression was assessed semiquantitatively.. High levels of endothelial E-selectin and proximal tubular expression of HLA-DR antigens, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 were detected in biopsies from cadaveric kidneys, whereas expression of these markers was markedly reduced in LRD kidneys. High levels of tubular antigen expression were significantly associated with traumatic death, prolonged ventilation, and episodes of infection in cadaver donors. Furthermore, the expression of pretransplant tubular antigens in cadaver donor kidneys was significantly associated with early acute rejection following transplantation, suggesting that such kidneys are predisposed to subsequent immune-mediated attack following transplantation.. These results may explain, in part, the superior outcome of LRD allografts compared with cadaver renal allografts. Topics: Adult; Antibodies, Monoclonal; Biopsy; Cadaver; Deamino Arginine Vasopressin; E-Selectin; Endothelium; Female; Graft Survival; Histocompatibility Antigens Class II; HLA-DR Antigens; Humans; Intensive Care Units; Intercellular Adhesion Molecule-1; Kidney Transplantation; Kidney Tubules, Proximal; Living Donors; Male; Middle Aged; P-Selectin; Renal Agents; Transplantation Immunology; Transplantation, Homologous; Vascular Cell Adhesion Molecule-1 | 1999 |
3 other study(ies) available for deamino-arginine-vasopressin and Cadaver
Article | Year |
---|---|
The influence of desmopressin and vasopressors in the donor management on graft function following pancreas transplantation.
The use of desmopressin and vasopressors in cadaveric organ donors is considered a risk factor for graft dysfunction following pancreas transplantation by influencing the microcirculation. The aim of this study was to investigate the influence of these substances on early graft function.. This single-center retrospective trial included 59 patients who underwent simultaneous or solitary pancreas transplantation. The corresponding donor charts were reviewed for the use of vasopressors and desmopressin. Impaired graft function was determined as graft thrombosis or as insulin-dependence for more then 3 days posttransplant. Daily amylase and lipase concentrations from abdominal drains were measured to quantify reperfusion pancreatitis and fistula formation.. Overall, pancreas thrombosis was observed in 4 of 59 (6.8%) recipients. There were no significant differences in thrombosis rate whether the donors received desmopressin (3/38 vs 1/21, P >.1) or the needed vasopressors (3/53 vs 1/9, P >.1). The number of patients who required insulin for more than 3 days posttransplant was comparable whether the donors received desmopressin (9/38 vs 4/21, P >.1), or vasopressors (9/46 vs 3/8, P >.1). At present all recipients with functioning pancreatic grafts (ie, 92.7%) are free of exogenous insulin therapy at 2 to 80 months posttransplant. The amylase/lipase concentrations of peritoneal fluid were independent of the administration of desmopressin or vasopressors in the donors.. In this study donor desmopressin and vasopressor administration did not influence graft function after pancreas transplantation. Topics: Adult; Cadaver; Cause of Death; Deamino Arginine Vasopressin; Diabetes Mellitus, Type 1; Drainage; Female; Humans; Insulin; Kidney Transplantation; Male; Middle Aged; Organ Preservation; Pancreas Transplantation; Retrospective Studies; Tissue Donors; Treatment Outcome; Vasopressins | 2004 |
Does treatment of cadaveric organ donors with desmopressin increase the likelihood of pancreas graft thrombosis? Results of a preliminary study.
Desmopressin (DDAVP) is commonly used in cadaveric organ donors to treat diabetes insipidus. The thrombogenic potential of DDAVP is well known. Recent animal data have demonstrated that DDAVP impairs pancreas graft (PG) microcirculation and perfusion. The aim of this study was too evaluate the effect of DDAVP on the incidence of PG thrombosis in clinical pancreas transplantation. A retrospective review of simultaneous kidney-pancreas transplant (SKPT) entered in the Scientific Registry of Transplant Recipients (SRTR) between 10/5/87 and 9/27/02 was performed. Patients were included for analysis if there was definitive documentation as to whether DDAVP was (DDAVP-Y) or was not (DDAVP-N) administered to the donor. Both dose and duration of DDAVP treatment were not recorded by SRTR. A total of 2804 SKPTs were available for analysis. Mean follow-up was 1.75 years (range, 1 month to 8.4 years). A total of 1287 SKPT patients (46%) received a PG from a DDAVP-Y donor. Graft ischemia times, donor and recipient ages, recipient gender distribution, surgical techniques, and immunosuppressive regimens were similar in both groups. The overall incidence of PG thrombosis was 4.3%. The incidence of PG thrombosis in recipients of grafts from DDAVP-Y donors was 5.1% compared to 3.5% in recipients of grafts from DDAVP-N donors (P =.04). Fifty-eight percent of thrombosed PG came from DDAVP-Y donors compared to 42% from DDAVP-N donors (P =.04). We conclude that there appears to be a relationship between donor treatment with DDAVP and PG thrombosis. A prospective study is needed to verify these findings and to determine their clinical significance. Topics: Cadaver; Deamino Arginine Vasopressin; Female; Follow-Up Studies; Humans; Male; Pancreas; Pancreas Transplantation; Postoperative Complications; Retrospective Studies; Thrombosis; Time Factors; Tissue Donors | 2004 |
1-Desamino 8-D arginine-vasopressin in the diagnosis and treatment of central diabetes insipidus in a patient after cadaveric renal transplantation.
Topics: Arginine Vasopressin; Cadaver; Child; Deamino Arginine Vasopressin; Diabetes Insipidus; Female; Humans; Kidney Transplantation; Postoperative Complications | 1985 |